SYDNEY, AUSTRALIA – 4 October 2024 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces independent non-executive director (NED), Anne Anderson, has tendered her resignation effective from 4 October 2024. Accordingly, she will not seek election as a Director of the Company by shareholders at the Company’s upcoming Annual General Meeting.
Dr Russell Howard, Chairman of Immutep, said “Anne has been a valued member of the Board since her appointment in February 2024, contributing to the strength of our risk management and governance. On behalf of the Board, I would like to thank her for her contribution to the success of Immutep and wish her every success with her next endeavours.”
For more information, download the attached PDF.
Download this document